Researchers at Duke University School of Medicine have identified a small population of brain cells that may help determine whether opioids become linked to rewarding experiences—and potentially addictive behavior. The discovery, reported in Nature, challenges a long-standing assumption that opioid reward learning is driven primarily by dopamine and suggests that a second chemical signal, involving acetylcholine, may be essential for the brain to form powerful drug-related associations.
The findings come from experiments in mice focused on the nucleus accumbens, a brain region involved in motivation, emotion, reinforcement and learning. Opioids such as morphine produce profound effects in this area, including changes in dopamine release. These changes can teach the brain to associate the drug with a particular environment or experience, creating memories that may later encourage drug seeking. In the new study, however, researchers found that dopamine elevation alone did not appear to be sufficient to produce those learned preferences.
The team, led by Mike Tadross, MD, PhD, an assistant professor of neurosurgery at Duke, examined neurons in the nucleus accumbens that release acetylcholine. Unlike dopamine, which is often described as a reward-related chemical, acetylcholine is involved in attention, learning, memory and the regulation of neural circuits. The cholinergic neurons studied by the researchers form what appears to be a small but influential signaling hub capable of controlling how opioid exposure is translated into lasting behavioral learning.
Opioids relieve pain through several interconnected mechanisms. They can activate opioid receptors in the spinal cord and peripheral nervous system, reducing the transmission of pain signals before those signals reach the brain. They also act within the brain, changing how pain is interpreted emotionally. Rather than simply eliminating the physical sensation, opioids can reduce the unpleasantness or urgency associated with pain, allowing it to remain present without provoking the same level of distress.
That distinctive form of analgesia is one reason opioids are medically valuable—and also why their effects can be difficult to separate from their risks. When an opioid produces relief or emotional comfort, the brain can connect those effects with the drug itself, the surrounding environment or specific cues. Over time, these associations may contribute to craving and compulsive drug seeking. Understanding the neural circuitry responsible for those learned associations could therefore help researchers design treatments that preserve pain relief while reducing addiction liability.
To test the role of cholinergic neurons, the Duke researchers used a molecular targeting technology known as DART, or drugs acutely restricted by tethering. Developed in Tadross’s laboratory, the approach allows a drug to be directed selectively to a defined population of neurons. In this study, the researchers used a modified form of naloxone, an opioid antagonist, designed to block opioid receptors specifically on acetylcholine-releasing neurons in the nucleus accumbens while leaving opioid signaling elsewhere largely intact.
The temporary and targeted blockade produced a striking behavioral effect. Mice that received morphine no longer developed a preference for the chamber in which they had experienced the drug, a standard laboratory test called conditioned place preference. This result indicated that the animals were not forming the usual environmental association with morphine. Yet the intervention did not eliminate morphine’s pain-relieving effects. The animals continued to show analgesia, and morphine still increased dopamine levels in the nucleus accumbens.
According to the researchers, the key event may be an opioid-induced decrease in acetylcholine release from the cholinergic hub. In this model, dopamine may signal that something important or rewarding has occurred, while the reduction in acetylcholine helps the brain encode the connection between the drug and the surrounding context. Without that cholinergic change, dopamine elevation may not be enough to produce opioid reward learning. The result separates two effects that have often been treated as inseparable: opioid-induced dopamine signaling and the formation of learned drug preference.
The study also offers a possible explanation for conflicting results from earlier research. Previous experiments used genetic methods to remove opioid receptors from cholinergic neurons permanently, beginning early in development. The Duke team argues that the brain may have compensated for those lifelong changes by reorganizing its circuitry or altering signaling pathways. By contrast, DART allowed the researchers to block opioid receptors temporarily in adult animals, more closely modeling what might happen if a medication selectively interrupted the pathway after the brain had developed.
The findings remain preliminary because they were obtained in mice, and the nucleus accumbens, although evolutionarily conserved across mammals, is embedded in a far more complex human brain. Researchers must still determine whether the same cholinergic mechanism governs opioid reward learning in people, whether it can be targeted without impairing motivation or memory, and whether such an intervention could be converted into a safe medicine. Nevertheless, the work points to a promising strategy: rather than eliminating opioid activity throughout the nervous system, future therapies might selectively disrupt the neural pathway that teaches the brain to want the drug while preserving the analgesia that makes opioids clinically useful.
Subject of Research: Animals
Article Title: A cholinergic hub in the nucleus accumbens gates opioid-reward learning
News Publication Date: 5-Aug-2026
Web References: https://www.nature.com/articles/s41586-026-10887-9
References: Nature, DOI: 10.1038/s41586-026-10887-9
Keywords: Opioid addiction, morphine, pain relief, reward learning, nucleus accumbens, acetylcholine, dopamine, cholinergic neurons, opioid receptors, neuroscience, addiction research, naloxone, DART technology
